← Back to Search

SABR for Metastatic Prostate Cancer (ANCHORProstate Trial)

Phase 2
Recruiting
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trialwill investigate if SABR treatment helps men with metastatic prostate cancer live longer. 80 patients will be randomly selected to receive this experimental treatment.

Who is the study for?
This trial is for men with metastatic prostate cancer who are part of the PERa registry and have shown the best possible response to standard treatments, as seen by stable PSA levels. They should be able to perform daily activities (ECOG 0-2) and have a PSA greater than 0.2 ng/mL. Only those with 1-5 areas of cancer detectable on PSMA-PET scans that can be targeted by SABR will qualify.
What is being tested?
The ANCHOR-Prostate trial is testing whether adding a type of precise radiation therapy called SABR (Stereotactic Ablative Radiotherapy) after maximum response from usual drug treatments can help control prostate cancer better. The main goal is to see if patients remain free from disease progression one year after treatment.
What are the potential side effects?
While specific side effects are not listed here, SABR commonly includes risks such as fatigue, skin reactions in treated areas, urinary issues like increased frequency or discomfort, bowel changes including diarrhea or rectal bleeding, and potential impacts on sexual function.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
FFS
Secondary study objectives
Toxicity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: SABR consolidationExperimental Treatment1 Intervention
Group II: Control - no SABR consolidationActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SABR
2012
Completed Phase 2
~110

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
377 Previous Clinical Trials
131,440 Total Patients Enrolled
5 Trials studying Prostate Cancer
2,109 Patients Enrolled for Prostate Cancer

Media Library

SABR consolidation Clinical Trial Eligibility Overview. Trial Name: NCT05457699 — Phase 2
Prostate Cancer Research Study Groups: Control - no SABR consolidation, SABR consolidation
Prostate Cancer Clinical Trial 2023: SABR consolidation Highlights & Side Effects. Trial Name: NCT05457699 — Phase 2
SABR consolidation 2023 Treatment Timeline for Medical Study. Trial Name: NCT05457699 — Phase 2
~21 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top